Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 514

1.

HIV-1 Protease Uses Bi-Specific S2/S2' Subsites to Optimize Cleavage of Two Classes of Target Sites.

Potempa M, Lee SK, KurtYilmaz N, Nalivaika EA, Rogers A, Spielvogel E, Carter CW Jr, Schiffer CA, Swanstrom R.

J Mol Biol. 2018 Nov 7. pii: S0022-2836(18)31000-3. doi: 10.1016/j.jmb.2018.10.022. [Epub ahead of print]

PMID:
30414407
2.

LIP formation and protracted lower mantle upwelling induced by rifting and delamination.

Petersen KD, Schiffer C, Nagel T.

Sci Rep. 2018 Nov 8;8(1):16578. doi: 10.1038/s41598-018-34194-0.

3.

Mutations in influenza A virus neuraminidase and hemagglutinin confer resistance against a broadly neutralizing hemagglutinin stem antibody.

Prachanronarong KL, Canale AS, Liu P, Somasundaran M, Hou S, Poh YP, Han T, Zhu Q, Renzette N, Zeldovich KB, Kowalik TF, Kurt-Yilmaz N, Jensen JD, Bolon DNA, Marasco WA, Finberg RW, Schiffer CA, Wang JP.

J Virol. 2018 Oct 31. pii: JVI.01639-18. doi: 10.1128/JVI.01639-18. [Epub ahead of print]

PMID:
30381484
4.
5.

A call to arms: Unifying the fight against resistance.

Kaushansky A, Hedstrom L, Goldman A, Singh J, Yang PL, Rathod PK, Cynamon M, Wodarz D, Mahadevan D, Tomaras A, Navia MA, Schiffer CA.

Sci Signal. 2018 Oct 23;11(553). pii: eaav0442. doi: 10.1126/scisignal.aav0442.

PMID:
30352947
6.

Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis.

Seymour EK, Ruterbusch JJ, Beebe-Dimmer JL, Schiffer CA.

Cancer. 2018 Oct 21. doi: 10.1002/cncr.31738. [Epub ahead of print]

PMID:
30343488
7.

Synergistic activation of CatSper Ca2+ channels in human sperm by oviductal ligands and endocrine disrupting chemicals.

Brenker C, Rehfeld A, Schiffer C, Kierzek M, Kaupp UB, Skakkebæk NE, Strünker T.

Hum Reprod. 2018 Oct 1;33(10):1915-1923. doi: 10.1093/humrep/dey275.

PMID:
30189007
8.

Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease.

Matthew AN, Leidner F, Newton A, Petropoulos CJ, Huang W, Ali A, KurtYilmaz N, Schiffer CA.

Structure. 2018 Oct 2;26(10):1360-1372.e5. doi: 10.1016/j.str.2018.07.004. Epub 2018 Aug 23.

PMID:
30146168
9.

Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants.

Rusere LN, Matthew AN, Lockbaum GJ, Jahangir M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A.

ACS Med Chem Lett. 2018 May 17;9(7):691-696. doi: 10.1021/acsmedchemlett.8b00150. eCollection 2018 Jul 12.

PMID:
30034602
10.

T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response.

Moise L, M Biron B, Boyle CM, Kurt Yilmaz N, Jang H, Schiffer C, M Ross T, Martin WD, De Groot AS.

Hum Vaccin Immunother. 2018;14(9):2203-2207. doi: 10.1080/21645515.2018.1495303. Epub 2018 Sep 5.

11.

Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA.

Maiti A, Myint W, Kanai T, Delviks-Frankenberry K, Sierra Rodriguez C, Pathak VK, Schiffer CA, Matsuo H.

Nat Commun. 2018 Jun 25;9(1):2460. doi: 10.1038/s41467-018-04872-8.

12.

Impact of sphingolipids on osteoblast and osteoclast activity in Gaucher disease.

Reed MC, Schiffer C, Heales S, Mehta AB, Hughes DA.

Mol Genet Metab. 2018 Aug;124(4):278-286. doi: 10.1016/j.ymgme.2018.06.007. Epub 2018 Jun 14.

PMID:
29934064
13.

Substrate sequence selectivity of APOBEC3A implicates intra-DNA interactions.

Silvas TV, Hou S, Myint W, Nalivaika E, Somasundaran M, Kelch BA, Matsuo H, Kurt Yilmaz N, Schiffer CA.

Sci Rep. 2018 May 14;8(1):7511. doi: 10.1038/s41598-018-25881-z.

14.

The evolution of dasatinib dosage over the years and its relevance to other anticancer medications.

Schiffer CA.

Cancer. 2018 Jul 1;124(13):2687-2689. doi: 10.1002/cncr.31516. Epub 2018 May 3. No abstract available.

PMID:
29723416
15.

A novel cross-species inhibitor to study the function of CatSper Ca2+ channels in sperm.

Rennhack A, Schiffer C, Brenker C, Fridman D, Nitao ET, Cheng YM, Tamburrino L, Balbach M, Stölting G, Berger TK, Kierzek M, Alvarez L, Wachten D, Zeng XH, Baldi E, Publicover SJ, Benjamin Kaupp U, Strünker T.

Br J Pharmacol. 2018 Aug;175(15):3144-3161. doi: 10.1111/bph.14355. Epub 2018 Jun 29.

PMID:
29723408
16.

Assembly of human C-terminal binding protein (CtBP) into tetramers.

Bellesis AG, Jecrois AM, Hayes JA, Schiffer CA, Royer WE Jr.

J Biol Chem. 2018 Jun 8;293(23):9101-9112. doi: 10.1074/jbc.RA118.002514. Epub 2018 Apr 26.

PMID:
29700119
17.

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.

Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE.

BMC Cancer. 2018 Apr 2;18(1):359. doi: 10.1186/s12885-018-4273-1.

18.

Hydration Structure and Dynamics of Inhibitor-Bound HIV-1 Protease.

Leidner F, Kurt Yilmaz N, Paulsen J, Muller YA, Schiffer CA.

J Chem Theory Comput. 2018 May 8;14(5):2784-2796. doi: 10.1021/acs.jctc.8b00097. Epub 2018 Apr 18.

PMID:
29570286
19.

Synonymous Mutations at the Beginning of the Influenza A Virus Hemagglutinin Gene Impact Experimental Fitness.

Canale AS, Venev SV, Whitfield TW, Caffrey DR, Marasco WA, Schiffer CA, Kowalik TF, Jensen JD, Finberg RW, Zeldovich KB, Wang JP, Bolon DNA.

J Mol Biol. 2018 Apr 13;430(8):1098-1115. doi: 10.1016/j.jmb.2018.02.009. Epub 2018 Feb 18.

PMID:
29466705
20.

Probing Structural Changes among Analogous Inhibitor-Bound Forms of HIV-1 Protease and a Drug-Resistant Mutant in Solution by Nuclear Magnetic Resonance.

Khan SN, Persons JD, Paulsen JL, Guerrero M, Schiffer CA, Kurt-Yilmaz N, Ishima R.

Biochemistry. 2018 Mar 13;57(10):1652-1662. doi: 10.1021/acs.biochem.7b01238. Epub 2018 Feb 19.

PMID:
29457713
21.

Action of steroids and plant triterpenoids on CatSper Ca2+ channels in human sperm.

Brenker C, Schiffer C, Wagner IV, Tüttelmann F, Röpke A, Rennhack A, Kaupp UB, Strünker T.

Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E344-E346. doi: 10.1073/pnas.1717929115. Epub 2018 Jan 5. No abstract available.

22.

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.

DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA, Vandendries E, Liau K, Ananthakrishnan R, Boni J, Laird AD, Fostvedt L, Kantarjian HM, Advani AS.

Blood Adv. 2017 Jun 27;1(15):1167-1180. doi: 10.1182/bloodadvances.2016001925. eCollection 2017 Jun 27.

23.

Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope.

Avnir Y, Prachanronarong KL, Zhang Z, Hou S, Peterson EC, Sui J, Zayed H, Kurella VB, McGuire AT, Stamatatos L, Hilbert BJ, Bohn MF, Kowalik TF, Jensen JD, Finberg RW, Wang JP, Goodall M, Jefferis R, Zhu Q, Kurt Yilmaz N, Schiffer CA, Marasco WA.

Cell Rep. 2017 Dec 12;21(11):3243-3255. doi: 10.1016/j.celrep.2017.11.056.

24.

"Epigenetic" modification as therapy for acute myeloid leukemia.

Schiffer CA.

Cancer. 2018 Jan 15;124(2):242-244. doi: 10.1002/cncr.31137. Epub 2017 Dec 6. No abstract available.

PMID:
29211296
25.

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal.

Valent P, Akin C, Arock M, Bock C, George TI, Galli SJ, Gotlib J, Haferlach T, Hoermann G, Hermine O, Jäger U, Kenner L, Kreipe H, Majeti R, Metcalfe DD, Orfao A, Reiter A, Sperr WR, Staber PB, Sotlar K, Schiffer C, Superti-Furga G, Horny HP.

EBioMedicine. 2017 Dec;26:17-24. doi: 10.1016/j.ebiom.2017.11.024. Epub 2017 Nov 26. Review.

26.

Mavyret: A Pan-Genotypic Combination Therapy for the Treatment of Hepatitis C InfectionPublished as part of the Biochemistry series "Biochemistry to Bedside".

Matthew AN, Kurt Yilmaz N, Schiffer CA.

Biochemistry. 2018 Feb 6;57(5):481-482. doi: 10.1021/acs.biochem.7b01160. Epub 2017 Dec 1. No abstract available.

PMID:
29192768
27.

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Schiffer CA, Bohlke K, Delaney M, Hume H, Magdalinski AJ, McCullough JJ, Omel JL, Rainey JM, Rebulla P, Rowley SD, Troner MB, Anderson KC.

J Clin Oncol. 2018 Jan 20;36(3):283-299. doi: 10.1200/JCO.2017.76.1734. Epub 2017 Nov 28.

PMID:
29182495
28.

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

Schiffer CA, Bohlke K, Anderson KC.

J Oncol Pract. 2018 Feb;14(2):129-133. doi: 10.1200/JOP.2017.028902. Epub 2017 Nov 28. No abstract available.

PMID:
29182492
29.

Challenges in the Clinical Application of the American Society of Clinical Oncology Value Framework: A Medicare Cost-Benefit Analysis in Chronic Lymphocytic Leukemia.

Seymour EK, Schiffer CA, de Souza JA.

J Oncol Pract. 2017 Dec;13(12):e1002-e1011. doi: 10.1200/JOP.2017.024778. Epub 2017 Nov 16.

PMID:
29144866
30.

CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy.

Ma L, Boucher JI, Paulsen J, Matuszewski S, Eide CA, Ou J, Eickelberg G, Press RD, Zhu LJ, Druker BJ, Branford S, Wolfe SA, Jensen JD, Schiffer CA, Green MR, Bolon DN.

Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):11751-11756. doi: 10.1073/pnas.1708268114. Epub 2017 Oct 16.

31.

Elucidating the Interdependence of Drug Resistance from Combinations of Mutations.

Ragland DA, Whitfield TW, Lee SK, Swanstrom R, Zeldovich KB, Kurt-Yilmaz N, Schiffer CA.

J Chem Theory Comput. 2017 Nov 14;13(11):5671-5682. doi: 10.1021/acs.jctc.7b00601. Epub 2017 Oct 9.

32.

Citrullination of NF-κB p65 promotes its nuclear localization and TLR-induced expression of IL-1β and TNFα.

Sun B, Dwivedi N, Bechtel TJ, Paulsen JL, Muth A, Bawadekar M, Li G, Thompson PR, Shelef MA, Schiffer CA, Weerapana E, Ho IC.

Sci Immunol. 2017 Jun 9;2(12). pii: eaal3062. doi: 10.1126/sciimmunol.aal3062.

33.

Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants.

Matthew AN, Zephyr J, Hill CJ, Jahangir M, Newton A, Petropoulos CJ, Huang W, Kurt-Yilmaz N, Schiffer CA, Ali A.

J Med Chem. 2017 Jul 13;60(13):5699-5716. doi: 10.1021/acs.jmedchem.7b00426. Epub 2017 Jun 19.

34.

Crystal structure of APOBEC3A bound to single-stranded DNA reveals structural basis for cytidine deamination and specificity.

Kouno T, Silvas TV, Hilbert BJ, Shandilya SMD, Bohn MF, Kelch BA, Royer WE, Somasundaran M, Kurt Yilmaz N, Matsuo H, Schiffer CA.

Nat Commun. 2017 Apr 28;8:15024. doi: 10.1038/ncomms15024.

35.

Transplantation for Myeloma - Now or Later?

Schiffer CA, Zonder JA.

N Engl J Med. 2017 Apr 6;376(14):1378-1379. doi: 10.1056/NEJMe1700453. No abstract available.

PMID:
28379801
36.

Interdependence of Inhibitor Recognition in HIV-1 Protease.

Paulsen JL, Leidner F, Ragland DA, Kurt Yilmaz N, Schiffer CA.

J Chem Theory Comput. 2017 May 9;13(5):2300-2309. doi: 10.1021/acs.jctc.6b01262. Epub 2017 Apr 11.

37.

Point: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML.

Schiffer CA.

Oncology (Williston Park). 2017 Mar 15;31(3):190-1. No abstract available.

38.

Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side.

Lin KH, Ali A, Rusere L, Soumana DI, Kurt Yilmaz N, Schiffer CA.

J Virol. 2017 Apr 28;91(10). pii: e00045-17. doi: 10.1128/JVI.00045-17. Print 2017 May 15.

39.

Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase.

Prachanronarong KL, Özen A, Thayer KM, Yilmaz LS, Zeldovich KB, Bolon DN, Kowalik TF, Jensen JD, Finberg RW, Wang JP, Kurt-Yilmaz N, Schiffer CA.

J Chem Theory Comput. 2016 Dec 13;12(12):6098-6108. Epub 2016 Nov 17.

PMID:
27951676
40.

Structural and molecular analysis of a protective epitope of Lyme disease antigen OspA and antibody interactions.

Shandilya S, Kurt Yilmaz N, Sadowski A, Monir E, Schiller ZA, Thomas WD Jr, Klempner MS, Schiffer CA, Wang Y.

J Mol Recognit. 2017 May;30(5). doi: 10.1002/jmr.2595. Epub 2016 Nov 16.

41.

Dengue Protease Substrate Recognition: Binding of the Prime Side.

Lin KH, Nalivaika EA, Prachanronarong KL, Yilmaz NK, Schiffer CA.

ACS Infect Dis. 2016 Oct 14;2(10):734-743. Epub 2016 Sep 22.

42.

Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.

Soumana DI, Kurt Yilmaz N, Ali A, Prachanronarong KL, Schiffer CA.

J Am Chem Soc. 2016 Sep 14;138(36):11850-9. doi: 10.1021/jacs.6b06454. Epub 2016 Sep 2.

43.

Commentary on: 'Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia'.

Schiffer CA.

Leukemia. 2016 Aug;30(8):1636-7. doi: 10.1038/leu.2016.141. Epub 2016 Jun 10. No abstract available.

PMID:
27282253
44.

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G.

Am J Hematol. 2016 Sep;91(9):869-74. doi: 10.1002/ajh.24423. Epub 2016 Jun 20.

45.

Improving Viral Protease Inhibitors to Counter Drug Resistance.

Kurt Yilmaz N, Swanstrom R, Schiffer CA.

Trends Microbiol. 2016 Jul;24(7):547-557. doi: 10.1016/j.tim.2016.03.010. Epub 2016 Apr 15. Review.

46.

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.

Schiffer CA, Cortes JE, Hochhaus A, Saglio G, le Coutre P, Porkka K, Mustjoki S, Mohamed H, Shah NP.

Cancer. 2016 May 1;122(9):1398-407. doi: 10.1002/cncr.29933. Epub 2016 Mar 21.

47.

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Conti RM.

J Natl Cancer Inst. 2016 Mar 4;108(7). doi: 10.1093/jnci/djw003. Print 2016 Jul.

48.

The artful management of older patients with acute myeloid leukemia.

Yang J, Schiffer CA.

Expert Rev Hematol. 2016 May;9(5):425-32. doi: 10.1586/17474086.2016.1153963. Epub 2016 Mar 2. Review.

PMID:
26878693
49.

Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172.

Soumana DI, Kurt Yilmaz N, Prachanronarong KL, Aydin C, Ali A, Schiffer CA.

ACS Chem Biol. 2016 Apr 15;11(4):900-9. doi: 10.1021/acschembio.5b00647. Epub 2016 Jan 6.

50.

A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance.

Jiang L, Liu P, Bank C, Renzette N, Prachanronarong K, Yilmaz LS, Caffrey DR, Zeldovich KB, Schiffer CA, Kowalik TF, Jensen JD, Finberg RW, Wang JP, Bolon DNA.

J Mol Biol. 2016 Feb 13;428(3):538-553. doi: 10.1016/j.jmb.2015.11.027. Epub 2015 Dec 4.

PMID:
26656922

Supplemental Content

Loading ...
Support Center